Healthcare
Live Price
Offline$21.53
+0.00% today
Window Change
+232.25%
Window
Jun 23, 2025 → Apr 24, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 212 bars · Jun 23, 2025 → Apr 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Day One Biopharmaceuticals, Inc. (DAWN) is a Healthcare stock with a market cap of $2.22B and listed on NASDAQ. The stock last traded around $21.53 and up 232.3% across the available one-year price window (Jun 23, 2025 → Apr 24, 2026). Baseline metrics include revenue growth of +20.6%, EPS growth of -2.0%, a dividend yield of 0.0%. What stands out right now is revenue +20.6%, EPS -2.0%, free cash flow -29.6% with operating margin -80.8% and ROIC -28.0%. Valuation already assumes a fairly strong business story at price/sales 14.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DAWN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
DAWN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
DAWN Max Drawdown
-23.55%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for DAWN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$70.6M
+50.3% YoY
Free Cash Flow
-$56.5M
+48.6% YoY
Revenue Growth
+20.6%
EPS Growth
-2.0%
Gross Margin
89.1%
Net Margin
-67.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 158M | 131M | 0 | 0 | 0 |
| Gross Profit | 141M | 126M | -383K | -531K | -199K |
| Operating Income | -128M | -217M | -206M | -147M | -73M |
| EBITDA | -106M | -86M | -189M | -142M | -73M |
| Net Income | -107M | -95M | -189M | -142M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 197M | 125M | 231M | 85M | 284M |
| Total Assets | 508M | 583M | 376M | 349M | 290M |
| Total Liabilities | 67M | 80M | 30M | 17M | 9M |
| Shareholder Equity | 441M | 503M | 347M | 332M | 281M |
| Total Debt | 3M | 3M | 408K | 813K | 220K |
| Net Debt | -194M | -122M | -230M | -84M | -284M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
49M
+55.8% YoY
Capital Expenditures
8M
-30669.2% YoY
Free Cash Flow
57M
+48.6% YoY
Key ratios
Gross Margin
89.1%
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-23.4%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.